Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Premier Health of America Inc V.PHA

Alternate Symbol(s):  PRHAF

Premier Health of America Inc. is a Canadian healthtech company. The Company provides a comprehensive range of outsourced service solutions for healthcare needs to governments, corporations, and individuals. The Company uses its proprietary LiPHe platform to lead the healthcare services sector in digital transformation to provide patients with more accessible care services. The Company operates through two segments: Per Diem and Travel Nurses. The Per Diem segment includes Premier Soin and Code Bleu, two of its Quebec subsidiaries that offer their respective services for nursing and assistance by profile and by region. The Travel nurse segment includes Canadian Health Care Agency, Premier Soin Nordik, Solutions Nursing as well as Solutions Staffing, four of its subsidiaries that offer their respective services to the federal and provincial governments for nursing and assistance, including in remote regions.


TSXV:PHA - Post by User

Comment by Torontojayon Jun 07, 2022 6:35am
96 Views
Post# 34736185

RE:RE:Updated estimates of FY2022 finances

RE:RE:Updated estimates of FY2022 finances

$7.4m in ebitda using a 10 times multiple gives us a share price of ($74 - $5.73 - $14.5)m  divided by the total number of shares outstanding (55.84m) gives a share price of about 93 cents. If we use a 14 times multiple then a fair price would be $1.49. 

$8.6m in ebitda using a 10 times multiple gives us a share price of $1.18. At 14 times we get a price of $1.79. 

Given the parameters above, I would say we should trade anywhere between 93 cents to as high as $1.79 over the next year if these ebitda targets are achieved. 

Next post I will examine how much of ebitda gets converted to free cash flow. 

<< Previous
Bullboard Posts
Next >>